^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners

    TEST:
    PanHeme assay

    Company:
    Roswell Park Comprehensive Cancer Center
    Type:
    Laboratory Developed Test

    Details

    Evidence
    News
    PanHeme, an assay used to support the clinical care of patients with blood cancers, including leukemias, lymphomas and myeloma, is a next-generation-sequencing (NGS) technology that can identify mutations in hundreds of genes in under 72 hours — a dramatic improvement over the three- to four-week wait time for the current leading NGS molecular test.
    Cancer:
    Leukemia, Lymphoma, Multiple Myeloma
    Method:
    Next-Generation Sequencing (NGS)